Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash & Equivalents (2016 - 2025)

IGC Pharma has reported Cash & Equivalents over the past 16 years, most recently at $1.1 million for Q3 2025.

  • Quarterly Cash & Equivalents fell 28.53% to $1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Sep 2025, down 28.53% year-over-year, with the annual reading at $405000.0 for FY2025, 66.19% down from the prior year.
  • Cash & Equivalents was $1.1 million for Q3 2025 at IGC Pharma, up from $454000.0 in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $14.5 million in Q1 2021 and troughed at $405000.0 in Q1 2025.
  • The 5-year median for Cash & Equivalents is $3.0 million (2023), against an average of $5.3 million.
  • Year-over-year, Cash & Equivalents skyrocketed 1151.0% in 2021 and then tumbled 78.6% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $11.9 million in 2021, then crashed by 58.59% to $4.9 million in 2022, then tumbled by 72.13% to $1.4 million in 2023, then tumbled by 65.89% to $470000.0 in 2024, then skyrocketed by 135.11% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Cash & Equivalents are $1.1 million (Q3 2025), $454000.0 (Q2 2025), and $405000.0 (Q1 2025).